AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CRISPR Therapeutics AG Director's Dealing 2017

May 6, 2017

30936_dirs_2017-05-05_d82264ef-f297-4e96-90d4-3b6d6c6f8ed3.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2017-05-03

Reporting Person: Kulkarni Samarth (Please See Remarks)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-05-03	Stock Options (Right to Buy)	$16.21	A	100000	Acquired	2027-05-03	Common Shares (100000)	Direct

Footnotes

F1: This option was granted on May 3, 2017 with respect to 100,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning May 31, 2017.